Elektrofi inks up to $470 million deal with Lilly

Boston, USA-based biotech Elektrofi has entered a multi-target research collaboration and license agreement with US pharma major Eli Lilly (NYSE: LLY) to develop next-generation medicines that can be delivered subcutaneously.

Elektrofi said the deal strengthens its position as a global partner and scientific technology innovator that is reformulating the future of biologic delivery through its proprietary ultra-high concentration microparticle suspension technology platform.

“We are in an exciting era of patient-centered care and believe patients have a right to receive life-changing therapies on their terms,” said Chase Coffman, chief executive of Elektrofi, adding: “Our collaboration with Lilly further validates the potential value of our expertise, our capabilities, and our proprietary technology platform, especially in the areas of autoimmune disease, oncology, and neuroscience. Our team is looking forward to collaborating with Lilly and leveraging the talents and insights of the collective team to accomplish what is yet to be done.”